Skip to content

Author

G. Gobbi

We have 7 of 17 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

469. The serotonin 5-HT2A agonist psilocybin in the treatment of neuropathic pain

Abstract Background Pain conditions are major health problems resulting in physical, psychological and social impairment (1), and health care costs (2,3). Within the last decade, research has demonstrated that 5-HT2A agonists including psilocybin and LSD elicit spiritual experiences (4) and functional connectivity chan...

E. Nield, M. López-Canúl, A. Inserra et al. · 0 citations
Open access Sep 2026

300. Delta-9-tetrahydrocannabinol (THC) alleviates neuropathic pain and insomnia through activation of the reticular thalamus

Acute systemic THC dose-dependently reduced SNL-induced mechanical allodynia and normalized sleep–wake architecture in NP rats, suggesting THC has potential therapeutic value for neuropathic pain with comorbid insomnia.

M. López-Canúl, A. Oveisi, M. Vigano et al. · 0 citations
Open access Sep 2026

805. Rapid Antidepressant-Like Effects of 5-MeO-DMT Require Both 5-HT1A and 5-HT2A Receptors

Results establish that 5-HT1A and 5-HT2A receptors mediate the rapid antidepressant-like effects of 5-MeO-DMT and establish how receptor-specific antagonism modulates associated serotonergic behavioral outputs.

B. Richardson, S. Socolow, M. López-Canúl et al. · 0 citations
Open access Sep 2026

859. From Neurons to Behavior: Preclinical Insights into LSD’s Anxiolytic Mechanisms

Findings suggest that while acute LSD, at high doses decreases decreased theta, beta, and gamma power and 5-HT firing activity, after repeated LSD may counteract stress-induced anxiety by enhancing cortical synaptic plasticity and serotonergic neurotransmission, potentially via 5-HT₁A receptor desensitization at the pr...

G. Gobbi · 0 citations
Open access Sep 2026

562. Repeated psilocybin administration does not induce rewarding effects and increases ventral tegmental dopaminergic activity during withdrawal

Abstract Background Psilocybin has shown therapeutic potential for several neuropsychiatric disorders; however, concerns remain regarding its abuse liability and long-term neurobiological effects following repeated use. While acute psychedelic administration is generally considered to have low addictive potential, the...

V. Bruno, M. López-Canúl, B. Richardson et al. · 0 citations
Review Open access Sep 2026

860. Glutamatergic Signaling and Neuroplasticity in Mood Disorders: A Historical Perspective from Preclinical Discoveries to Clinical Translation

A narrative review integrating preclinical and clinical studies investigating glutamatergic mechanisms in mood disorders, focusing on NMDA and AMPA receptor dynamics, intracellular signaling pathways (including mTORC1 and eIF4E-dependent translation), and circuit-level adaptations.

G. Gobbi · 0 citations
Open access Sep 2026

677. Effects of cannabidiol on social behaviour of Shank3 and Fmr1 mutant mice

These findings highlight the potential for CBD as a treatment for social deficits in syndromic autism and indicate that the therapeutic effect may be driven by dose-, sex-, or strain-specific mechanisms.

M. Parkhill, S. Baglot, V. Lewis et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.